Merck to Showcase New Data Across MS Portfolio at EAN 2019

Not intended for UK or U.S. based media

Darmstadt, Germany (ots/PRNewswire) -

- Company to present 16 abstracts on MAVENCLAD® (cladribine tablets),
Rebif® (interferon beta-1a) and investigational evobrutinib at the
5th Congress of the European Academy of Neurology
- Presentations include new data on the long-term efficacy and safety
of MAVENCLAD®, new safety data for Rebif® and the 48-week analysis
from the Phase 2 clinical study with evobrutinib
- Merck-initiative MS in the 21st Century to present findings from
Patient Perceptions Initiative

Merck, a leading science and technology company, today announced
that data from across its multiple sclerosis (MS) portfolio will be
presented at the 5th Congress of the European Academy of Neurology
(EAN), 29 June - 2 July 2019 in Oslo, Norway. Merck will present a
total of 16 abstracts (12 posters and 4 presentations) on MAVENCLAD®
(cladribine tablets), Rebif® (interferon beta-1a) and the
investigational therapy evobrutinib (an oral, highly selective
Bruton's Tyrosine Kinase [BTK] inhibitor). The company will also
present findings from the Patient Perceptions Initiative by MS in the
21st Century.

"The wealth of new data that we are presenting at EAN 2019, from
both our approved medicines and our pipeline in MS, highlight our
commitment to making further advances for people living with this
chronic disease," said Luciano Rossetti, Head of Global Research &
Development for the Biopharma business of Merck.

Key MAVENCLAD® data will include:

- Post-hoc analysis of the CLARITY Extension study to examine the
long-term efficacy in high-disease activity patients treated with
cladribine tablets 3.5 mg/kg
- Updated safety analysis of cladribine tablets 3.5 mg/kg in patients
with relapsing multiple sclerosis (RMS)

Key Rebif® data will include:

- Results from the Nordic registry regarding the risk of spontaneous
abortion and ectopic pregnancy in patients using interferons
- Results from the UK Multiple Sclerosis Risk Sharing Scheme on
treatment with subcutaneous interferon beta-1a

Key evobrutinib data will include:

- Results of analysis of the efficacy and safety of evobrutinib in
patients with RMS over 48 Weeks: a randomized, placebo-controlled,
phase 2 study

In addition, Merck will be presenting results from a global
mapping study supported by the MS in the 21st Century initiative. The
results will outline the availability of educational resources in MS
across several themes including 'MS stages and progression'. The
initiative, led by a steering group of international MS specialists,
aims to gain insight into patient opinions on unmet needs in MS
management.

Below is a selection of abstracts that have been accepted for
presentation at EAN 2019:

MAVENCLAD®
(cladribine
tablets)
Title Lead Poster Presentation
Author / Session
NEDA-3 durability (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=338bc0bf-0c82-45ba-a438-9f0948d96ea2&t=browsepresentations) Giovannoni EPO1244 Session: "MS
in CLARITY (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=338bc0bf-0c82-45ba-a438-9f0948d96ea2&t=browsepresentations) G and related
Extension in (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=338bc0bf-0c82-45ba-a438-9f0948d96ea2&t=browsepresentations) disorders 3"
patients with (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=338bc0bf-0c82-45ba-a438-9f0948d96ea2&t=browsepresentations) Date:
relapsing multiple (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=338bc0bf-0c82-45ba-a438-9f0948d96ea2&t=browsepresentations) Saturday, 29
sclerosis receiving (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=338bc0bf-0c82-45ba-a438-9f0948d96ea2&t=browsepresentations) June 2019
Cladribine Tablets (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=338bc0bf-0c82-45ba-a438-9f0948d96ea2&t=browsepresentations) Time: 12:30
to 13:15
Location:
Screen B12
Variations of uric (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=9b233edd-ea63-4f15-ac5c-12b4ddaafed4&t=browsepresentations) Moccia M EPO2218 Session: "MS
acid levels and (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=9b233edd-ea63-4f15-ac5c-12b4ddaafed4&t=browsepresentations) and related
their clinical (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=9b233edd-ea63-4f15-ac5c-12b4ddaafed4&t=browsepresentations) disorders 5"
correlates during (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=9b233edd-ea63-4f15-ac5c-12b4ddaafed4&t=browsepresentations) Date: Sunday
cladribine (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=9b233edd-ea63-4f15-ac5c-12b4ddaafed4&t=browsepresentations) 30 June 2019
treatment (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=9b233edd-ea63-4f15-ac5c-12b4ddaafed4&t=browsepresentations) Time: 12:30
to 13:15
Location:
Screen B11
CLARITY Extension: (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=cd3a9846-d942-46a8-9f69-84a632aa348b&t=browsepresentations) Vermersch EPO3211 Session: "MS
Sustained efficacy (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=cd3a9846-d942-46a8-9f69-84a632aa348b&t=browsepresentations) P and related
in relapsing (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=cd3a9846-d942-46a8-9f69-84a632aa348b&t=browsepresentations) disorders 8"
remitting multiple (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=cd3a9846-d942-46a8-9f69-84a632aa348b&t=browsepresentations) Date: Monday,
sclerosis following (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=cd3a9846-d942-46a8-9f69-84a632aa348b&t=browsepresentations) 01 July 2019
switch from (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=cd3a9846-d942-46a8-9f69-84a632aa348b&t=browsepresentations) Time: 12:30
Cladribine Tablets (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=cd3a9846-d942-46a8-9f69-84a632aa348b&t=browsepresentations) to 13:15
to placebo in (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=cd3a9846-d942-46a8-9f69-84a632aa348b&t=browsepresentations) Location:
patients with high (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=cd3a9846-d942-46a8-9f69-84a632aa348b&t=browsepresentations) Screen B11
disease activity at (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=cd3a9846-d942-46a8-9f69-84a632aa348b&t=browsepresentations)
baseline (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=cd3a9846-d942-46a8-9f69-84a632aa348b&t=browsepresentations)
Rationale, design (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=f773859c-e7dd-458e-be4a-a1341808aeec&t=browsepresentations) Boyko A POD026 Session:
and feasibility (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=f773859c-e7dd-458e-be4a-a1341808aeec&t=browsepresentations) "Poster on
assessment of the (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=f773859c-e7dd-458e-be4a-a1341808aeec&t=browsepresentations) Display
phase IV CLASSIC-MS (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=f773859c-e7dd-458e-be4a-a1341808aeec&t=browsepresentations) Date:
study evaluating (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=f773859c-e7dd-458e-be4a-a1341808aeec&t=browsepresentations) Saturday 29
long-term efficacy (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=f773859c-e7dd-458e-be4a-a1341808aeec&t=browsepresentations) June-Monday 1
outcomes for (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=f773859c-e7dd-458e-be4a-a1341808aeec&t=browsepresentations) July
patients with (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=f773859c-e7dd-458e-be4a-a1341808aeec&t=browsepresentations)
multiple sclerosis (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=f773859c-e7dd-458e-be4a-a1341808aeec&t=browsepresentations)
treated with (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=f773859c-e7dd-458e-be4a-a1341808aeec&t=browsepresentations)
Cladribine Tablets (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=f773859c-e7dd-458e-be4a-a1341808aeec&t=browsepresentations)
Incidence and risk (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=8b2607b9-8b06-45ec-b949-e292fd655b29&t=browsepresentations) Kuiper J EPO2202 Session: "MS
of any malignancies (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=8b2607b9-8b06-45ec-b949-e292fd655b29&t=browsepresentations) and Related
in multiple (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=8b2607b9-8b06-45ec-b949-e292fd655b29&t=browsepresentations) Disorders 4"
sclerosis (MS) from (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=8b2607b9-8b06-45ec-b949-e292fd655b29&t=browsepresentations) Date: Sunday
the Netherlands (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=8b2607b9-8b06-45ec-b949-e292fd655b29&t=browsepresentations) 30 June 2019
(NL) and Denmark (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=8b2607b9-8b06-45ec-b949-e292fd655b29&t=browsepresentations) Time: 12:30
(DK) (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=8b2607b9-8b06-45ec-b949-e292fd655b29&t=browsepresentations) to 13:15
Location:
Screen B10
Incidence and risk (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=159b3e14-8f5b-481a-983b-f4a662d44e58&t=browsepresentations) Nørgaard M EPO2226 Session: "MS
of malignancies by (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=159b3e14-8f5b-481a-983b-f4a662d44e58&t=browsepresentations) and related
type, in multiple (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=159b3e14-8f5b-481a-983b-f4a662d44e58&t=browsepresentations) disorders 6"
sclerosis (MS) (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=159b3e14-8f5b-481a-983b-f4a662d44e58&t=browsepresentations) Date: Sunday,
patients, compared (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=159b3e14-8f5b-481a-983b-f4a662d44e58&t=browsepresentations) 30 June 2019
from the (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=159b3e14-8f5b-481a-983b-f4a662d44e58&t=browsepresentations) Time: 12:30
Netherlands (NL) (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=159b3e14-8f5b-481a-983b-f4a662d44e58&t=browsepresentations) -13:15
and Denmark (DK) (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=159b3e14-8f5b-481a-983b-f4a662d44e58&t=browsepresentations) Location:
Screen B12
Severity and (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=b89fce74-8cd0-4f30-8599-20726530acda&t=browsepresentations) Schippling EPO3196 Session: "MS
frequency of (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=b89fce74-8cd0-4f30-8599-20726530acda&t=browsepresentations) S and related
relapses in (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=b89fce74-8cd0-4f30-8599-20726530acda&t=browsepresentations) disorders 7"
patients with (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=b89fce74-8cd0-4f30-8599-20726530acda&t=browsepresentations) Date: Monday,
relapsing-remitting (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=b89fce74-8cd0-4f30-8599-20726530acda&t=browsepresentations) 01 July 2019
MS treated with (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=b89fce74-8cd0-4f30-8599-20726530acda&t=browsepresentations) Time: 12:30
Cladribine Tablets (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=b89fce74-8cd0-4f30-8599-20726530acda&t=browsepresentations) to 13:15
in CLARITY and (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=b89fce74-8cd0-4f30-8599-20726530acda&t=browsepresentations) Location:
placebo in CLARITY (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=b89fce74-8cd0-4f30-8599-20726530acda&t=browsepresentations) Screen B10
Extension (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=b89fce74-8cd0-4f30-8599-20726530acda&t=browsepresentations)
CLARITY/CLARITY (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=4a525790-afa7-416d-b670-6ea851a2093d&t=browsepresentations) Cook S POD049 Poster on
Extension: (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=4a525790-afa7-416d-b670-6ea851a2093d&t=browsepresentations) Display
Lymphopenia rates (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=4a525790-afa7-416d-b670-6ea851a2093d&t=browsepresentations) Date:
are consistent in (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=4a525790-afa7-416d-b670-6ea851a2093d&t=browsepresentations) Saturday 29
patients with and (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=4a525790-afa7-416d-b670-6ea851a2093d&t=browsepresentations) June-Monday 1
without high (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=4a525790-afa7-416d-b670-6ea851a2093d&t=browsepresentations) July
disease activity at (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=4a525790-afa7-416d-b670-6ea851a2093d&t=browsepresentations)
baseline (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=4a525790-afa7-416d-b670-6ea851a2093d&t=browsepresentations)
Treatment of (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=8e3d5f94-876b-40b1-b7da-a58347ff81fe&t=browsepresentations) Cook S POD050 Poster on
patients with (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=8e3d5f94-876b-40b1-b7da-a58347ff81fe&t=browsepresentations) Display
Multiple Sclerosis: (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=8e3d5f94-876b-40b1-b7da-a58347ff81fe&t=browsepresentations) Date:
An updated safety (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=8e3d5f94-876b-40b1-b7da-a58347ff81fe&t=browsepresentations) Saturday 29
analysis of (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=8e3d5f94-876b-40b1-b7da-a58347ff81fe&t=browsepresentations) June-Monday 1
Cladribine Tablets (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=8e3d5f94-876b-40b1-b7da-a58347ff81fe&t=browsepresentations) July
Efficacy of (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=f1a0dff4-8201-4fed-b12e-e110bf4ddc99&t=browsepresentations) Giovannoni EPO1243 Session: "MS
Cladribine Tablets (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=f1a0dff4-8201-4fed-b12e-e110bf4ddc99&t=browsepresentations) G and related
3.5 mg/kg in (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=f1a0dff4-8201-4fed-b12e-e110bf4ddc99&t=browsepresentations) disorders 3"
Patients with (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=f1a0dff4-8201-4fed-b12e-e110bf4ddc99&t=browsepresentations) Date:
Relapsing Multiple (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=f1a0dff4-8201-4fed-b12e-e110bf4ddc99&t=browsepresentations) Saturday, 29
Sclerosis (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=f1a0dff4-8201-4fed-b12e-e110bf4ddc99&t=browsepresentations)Aged Above (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=f1a0dff4-8201-4fed-b12e-e110bf4ddc99&t=browsepresentations) June 2019
and Below 45 Years; (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=f1a0dff4-8201-4fed-b12e-e110bf4ddc99&t=browsepresentations) Time: 12:30
CLARITY and CLARITY (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=f1a0dff4-8201-4fed-b12e-e110bf4ddc99&t=browsepresentations) to 13:15
Extension (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=f1a0dff4-8201-4fed-b12e-e110bf4ddc99&t=browsepresentations) Location:
Screen B12
Evobrutinib
Bruton's Tyrosine (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=c0b4dce3-d362-45da-87bb-2bf720f50f71&t=browsepresentations) Montalban Oral Session: "MS
Kinase Inhibitor (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=c0b4dce3-d362-45da-87bb-2bf720f50f71&t=browsepresentations) X presentation and related
Evobrutinib (M2951) (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=c0b4dce3-d362-45da-87bb-2bf720f50f71&t=browsepresentations) - O1205 disorders"
in Patients with (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=c0b4dce3-d362-45da-87bb-2bf720f50f71&t=browsepresentations) Date:
Relapsing Multiple (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=c0b4dce3-d362-45da-87bb-2bf720f50f71&t=browsepresentations) Saturday, 29
Sclerosis: a (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=c0b4dce3-d362-45da-87bb-2bf720f50f71&t=browsepresentations) June 2019
Randomised, (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=c0b4dce3-d362-45da-87bb-2bf720f50f71&t=browsepresentations) Time: 17:30
Placebo-Controlled, (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=c0b4dce3-d362-45da-87bb-2bf720f50f71&t=browsepresentations)
Phase 2 Study (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=c0b4dce3-d362-45da-87bb-2bf720f50f71&t=browsepresentations)
Rebif® (interferon
beta-1a)
No increased risk (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=5c689561-e203-44be-9200-17d2c93bf70d&t=browsepresentations) Juuti R EPR2074 Session:
of spontaneous (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=5c689561-e203-44be-9200-17d2c93bf70d&t=browsepresentations) ePresentation
abortion and (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=5c689561-e203-44be-9200-17d2c93bf70d&t=browsepresentations) Date: Sunday,
ectopic pregnancy (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=5c689561-e203-44be-9200-17d2c93bf70d&t=browsepresentations) June 30Time:
after exposure to (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=5c689561-e203-44be-9200-17d2c93bf70d&t=browsepresentations) 13:30 to
interferon-beta (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=5c689561-e203-44be-9200-17d2c93bf70d&t=browsepresentations) 14:15Screen
prior to or during (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=5c689561-e203-44be-9200-17d2c93bf70d&t=browsepresentations) A6
pregnancy: Results (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=5c689561-e203-44be-9200-17d2c93bf70d&t=browsepresentations)
from register-based (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=5c689561-e203-44be-9200-17d2c93bf70d&t=browsepresentations)
Nordic study among (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=5c689561-e203-44be-9200-17d2c93bf70d&t=browsepresentations)
women with MS (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=5c689561-e203-44be-9200-17d2c93bf70d&t=browsepresentations)
Subcutaneous (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=efb08a4b-1220-4f48-8966-4972484a74de&t=browsepresentations) Harty G EPR1089 Session:
Interferon ?-1a: 10 (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=efb08a4b-1220-4f48-8966-4972484a74de&t=browsepresentations) ePresentation
years of the UK (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=efb08a4b-1220-4f48-8966-4972484a74de&t=browsepresentations) Date:
Multiple Sclerosis (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=efb08a4b-1220-4f48-8966-4972484a74de&t=browsepresentations) Saturday 29
Risk Sharing Scheme (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=efb08a4b-1220-4f48-8966-4972484a74de&t=browsepresentations) JuneTime:
13:30 to
14:15 Screen
A7
A systematic review (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=44a4f90b-ff5d-4214-8c70-8007dd8363b0&t=browsepresentations) Sabidó M EPO3194 Session:
of relapse rates in (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=44a4f90b-ff5d-4214-8c70-8007dd8363b0&t=browsepresentations) ePosterDate:
patients with (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=44a4f90b-ff5d-4214-8c70-8007dd8363b0&t=browsepresentations) Monday 1 July
relapsing multiple (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=44a4f90b-ff5d-4214-8c70-8007dd8363b0&t=browsepresentations) Time: 12:30
sclerosis during (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=44a4f90b-ff5d-4214-8c70-8007dd8363b0&t=browsepresentations) to
pregnancy and (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=44a4f90b-ff5d-4214-8c70-8007dd8363b0&t=browsepresentations) 13:15Screen
breastfeeding (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=44a4f90b-ff5d-4214-8c70-8007dd8363b0&t=browsepresentations) B10
Rapid reduction of (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=3043647e-4614-44cb-beda-1e76b7c0bc46&t=browsepresentations) De Stefano EPR1086 Session:
lesion accumulation (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=3043647e-4614-44cb-beda-1e76b7c0bc46&t=browsepresentations) N ePresentation
in specific white (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=3043647e-4614-44cb-beda-1e76b7c0bc46&t=browsepresentations) Date:
matter tracts as (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=3043647e-4614-44cb-beda-1e76b7c0bc46&t=browsepresentations) Saturday 29
assessed by lesion (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=3043647e-4614-44cb-beda-1e76b7c0bc46&t=browsepresentations) JuneTime:
mapping in RR-MS (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=3043647e-4614-44cb-beda-1e76b7c0bc46&t=browsepresentations) 13:30 to
patients treated (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=3043647e-4614-44cb-beda-1e76b7c0bc46&t=browsepresentations) 14:15 Screen
with IFN beta-1a (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=3043647e-4614-44cb-beda-1e76b7c0bc46&t=browsepresentations) A7
Dynamics of (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=76de218e-2c79-486e-8173-79a2fd4c84dd&t=browsepresentations) De Stefano EPO1234 Session:
Pseudo-Atrophy in (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=76de218e-2c79-486e-8173-79a2fd4c84dd&t=browsepresentations) N ePosterDate:
RRMS Patients (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=76de218e-2c79-486e-8173-79a2fd4c84dd&t=browsepresentations) Saturday 29
Treated with (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=76de218e-2c79-486e-8173-79a2fd4c84dd&t=browsepresentations) JuneTime:
Interferon beta-1a (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=76de218e-2c79-486e-8173-79a2fd4c84dd&t=browsepresentations) 12:30 to
as Assessed by (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=76de218e-2c79-486e-8173-79a2fd4c84dd&t=browsepresentations) 13:15Screen
Monthly Brain MRI (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=76de218e-2c79-486e-8173-79a2fd4c84dd&t=browsepresentations) B11
MS in the 21st
Century
A sub-analysis of (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=e8d2af5c-2100-49c7-9825-f8a4e8cdd2f0&t=browsepresentations) Vermersch EPO1148 Session:
global mapping data (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=e8d2af5c-2100-49c7-9825-f8a4e8cdd2f0&t=browsepresentations) P ePosterDate:
on the availability (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=e8d2af5c-2100-49c7-9825-f8a4e8cdd2f0&t=browsepresentations) Saturday, 29
of online (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=e8d2af5c-2100-49c7-9825-f8a4e8cdd2f0&t=browsepresentations) June 2019
educational (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=e8d2af5c-2100-49c7-9825-f8a4e8cdd2f0&t=browsepresentations) Time: 12:30
resources for (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=e8d2af5c-2100-49c7-9825-f8a4e8cdd2f0&t=browsepresentations) to
multiple sclerosis (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=e8d2af5c-2100-49c7-9825-f8a4e8cdd2f0&t=browsepresentations) 13:15Screen
patients (https://ipp-ean19.netkey.at/index.php?p=recorddetail&rid=e8d2af5c-2100-49c7-9825-f8a4e8cdd2f0&t=browsepresentations) A5

All Merck Press Releases are distributed by e-mail at the same
time they become available on the Merck Website. Please go to
www.merckgroup.com/subscribe to register online, change your
selection or discontinue this service.

About MAVENCLAD®

MAVENCLAD® is a short-course oral therapy that selectively and
periodically targets lymphocytes thought to be integral to the
pathological process of relapsing MS (RMS). In August 2017, the
European Commission (EC) granted marketing authorization for
MAVENCLAD® for the treatment of relapsing forms of multiple sclerosis
(RMS) in the 28 countries of the European Union (EU) in addition to
Norway, Liechtenstein and Iceland. MAVENCLAD® has since then been
approved in more than 50 countries, including Canada and Australia
and most recently in the U.S. in March 2019.

Visit www.MAVENCLAD.com for more information.

The clinical development program for cladribine tablets includes:

- The CLARITY (Cladribine Tablets Treating MS Orally) study: a
two-year Phase III placebo-controlled study designed to evaluate
the efficacy and safety of cladribine tablets as a monotherapy in
patients with RRMS.
- The CLARITY extension study: a Phase III placebo-controlled study
following on from the CLARITY study, which evaluated the safety and
exploratory efficacy of cladribine tablets over two additional
years beyond the two-year CLARITY study, according to the treatment
assignment scheme for years 3 and 4.
- The ORACLE MS (Oral Cladribine in Early MS) study: a two-year Phase
III placebo-controlled study designed to evaluate the efficacy and
safety of cladribine tablets as a monotherapy in patients at risk
of developing MS (patients who have experienced a first clinical
event suggestive of MS).
- The ONWARD (Oral Cladribine Added ON to Interferon beta-1a in
Patients With Active Relapsing Disease) study: a Phase II
placebo-controlled study designed primarily to evaluate the safety
and tolerability of adding cladribine tablets treatment to patients
with relapsing forms of MS, who have experienced breakthrough
disease while on established interferon-beta therapy.
- PREMIERE (Prospective Observational Long-term Safety Registry of
Multiple Sclerosis) study: a long-term observational follow-up
safety registry of MS patients who participated in cladribine
tablets clinical studies.

In the two-year CLARITY study, the most commonly reported adverse
event (AE) in patients treated with cladribine tablets was
lymphopenia (26.7% with cladribine tablets and 1.8% for placebo). The
incidence of infections was 48.3% with cladribine tablets and 42.5%
with placebo, with 99.1% and 99.0% respectively rated
mild-to-moderate by investigators. Adverse Events reported in other
clinical studies were similar.

About Rebif®

Rebif® (interferon beta-1a) is a disease-modifying drug used to
treat relapsing forms of multiple sclerosis (MS) and is similar to
the interferon beta protein produced by the human body. The efficacy
of Rebif® in chronic progressive MS has not been established.
Interferon ß is thought to help reduce inflammation. The exact
mechanism is unknown.

Rebif®, which was approved in Europe in 1998 and in the US in
2002, is registered in more than 90 countries worldwide. Rebif® has
been proven to delay the progression of disability, reduce the
frequency of relapses and reduce MRI lesion activity and area*.

Rebif® can be administrated with the RebiSmart® electronic
auto-injection device (not approved in the US), or with the RebiDose®
single-use disposable pen, or the manual multidose injection pen
RebiSlide(TM). Rebif® can also be administered with the autoinjector
Rebiject II® or by manual injection using ready-to-use pre-filled
syringes. These injection devices are not approved in all countries.

In January 2012, the European commission approved the extension of
the indication of Rebif® in early multiple sclerosis. The extension
of the indication of Rebif® has not been submitted in the United
States.

Rebif® should be used with caution in patients with a history of
depression, liver disease, thyroid abnormalities and seizures. Most
commonly reported side effects are flu-like symptoms, injection site
disorders, elevation of liver enzymes and blood cell abnormalities.
Patients, especially those with depression, seizure disorders, or
liver problems, should discuss treatment with Rebif® with their
doctors.

*The exact correlation between MRI findings and the current or
future clinical status of patients, including disability progression,
is unknown.

Rebif® (interferon beta-1a) is approved in the United States for
relapsing forms of MS.

About Evobrutinib

Evobrutinib (M2951) is in clinical development to investigate its
potential as a treatment for multiple sclerosis (MS), rheumatoid
arthritis (RA) and systemic lupus erythematosus (SLE). It is an oral,
highly selective inhibitor of Bruton's tyrosine kinase (BTK) which is
important in the development and functioning of various immune cells
including B lymphocytes and macrophages. Evobrutinib is designed to
inhibit primary B cell responses such as proliferation and antibody
and cytokine release, without directly affecting T cells. BTK
inhibition is thought to suppress autoantibody-producing cells, which
preclinical research suggests may be therapeutically useful in
certain autoimmune diseases. Evobrutinib is currently under clinical
investigation and not approved for any use anywhere in the world.

About Multiple Sclerosis

Multiple sclerosis (MS) is a chronic, inflammatory condition of
the central nervous system and is the most common non-traumatic,
disabling neurological disease in young adults. It is estimated that
approximately 2.3 million people have MS worldwide. While symptoms
can vary, the most common symptoms of MS include blurred vision,
numbness or tingling in the limbs and problems with strength and
coordination. The relapsing forms of MS are the most common.

Merck in Neurology and Immunology

Merck has a long-standing legacy in neurology and immunology, with
significant R&D and commercial experience in multiple sclerosis (MS).
The company`s current MS portfolio includes two products for the
treatment of relapsing MS, with a robust pipeline focusing on
discovering new therapies that have the potential to modulate key
pathogenic mechanisms in MS. Merck aims to improve the lives of those
living with MS, by addressing areas of unmet medical needs.

The company`s robust immunology pipeline focuses on discovering
new therapies that have the potential to modulate key pathogenic
mechanisms in chronic diseases such as MS, systemic lupus
erythematosus (SLE) and forms of arthritis, including rheumatoid
arthritis (RA) and osteoarthritis (OA).

About Merck

Merck, a leading science and technology company, operates across
healthcare, life science and performance materials. Around 52,000
employees work to make a positive difference to millions of people's
lives every day by creating more joyful and sustainable ways to live.
From advancing gene editing technologies and discovering unique ways
to treat the most challenging diseases to enabling the intelligence
of devices - the company is everywhere. In 2018, Merck generated
sales of EUR 14.8 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been
key to Merck's technological and scientific advances. This is how
Merck has thrived since its founding in 1668. The founding family
remains the majority owner of the publicly listed company. Merck
holds the global rights to the Merck name and brand. The only
exceptions are the United States and Canada, where the business
sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma
in life science, and EMD Performance Materials.

Logo - https://mma.prnewswire.com/media/842717/MERCK__Logo

Your Contact
tone-brauti.fritzen@merckgroup.com
Phone: +49 151 1454 2694

ots Originaltext: Merck KGaA
Im Internet recherchierbar: http://www.presseportal.de

Original-Content von: Merck KGaA, übermittelt durch news aktuell